Charles River Laboratories International, Inc.
CRL · NYSE
12/31/2024 | 12/28/2024 | 12/31/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Market Cap | $9 | – | $12 | $11 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $3 | $3 | $3 | $3 |
| Enterprise Value | $12 | – | $15 | $14 |
| Revenue | – | $4 | $4 | $4 |
| % Growth | – | -1.9% | 3.9% | – |
| Gross Profit | – | $1 | $2 | $1 |
| % Margin | – | 32.9% | 36.4% | 36.8% |
| EBITDA | – | $1 | $1 | $1 |
| % Margin | – | 14.3% | 25% | 24.8% |
| Net Income | – | $0 | $0 | $0 |
| % Margin | – | 0.3% | 11.5% | 12.2% |
| EPS Diluted | – | 0.2 | 9.22 | 9.48 |
| % Growth | – | -97.8% | -2.7% | – |
| Operating Cash Flow | – | $1 | $1 | $1 |
| Capital Expenditures | – | -$0 | -$0 | -$0 |
| Free Cash Flow | – | $1 | $0 | $0 |